<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03416270</url>
  </required_header>
  <id_info>
    <org_study_id>REB# 17-5627.0</org_study_id>
    <nct_id>NCT03416270</nct_id>
  </id_info>
  <brief_title>ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure</brief_title>
  <acronym>ERADICATE-HF</acronym>
  <official_title>ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure: &quot;ERADICATE-HF&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to elucidate the mechanisms whereby the SGLT2i &quot;ertugliflozin&quot; modifies&#xD;
      cardiorenal interactions that regulate fluid volume and neurohormonal activation in patients&#xD;
      with type 2 diabetes and heart failure (T2D-HF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Newer agents called sodium glucose co-transporter-2 inhibitors (SGLT2i) have been developed&#xD;
      to improve glycemic control and lower hemoglobin A1c by increasing glycosuria. SGLT2i also&#xD;
      reduce blood pressure and albuminuria in T2D - possibly through natriuresis. Importantly, a&#xD;
      landmark trial &quot;EMPA-REG OUTCOME&quot; demonstrated that the SGLT2i &quot;empagliflozin&quot; is the first&#xD;
      anti- hyperglycemic agent to reduce mortality and HF risk, and also to decrease the risk of&#xD;
      progressive diabetic nephropathy. Similar benefits were also recently reported in the CANVAS&#xD;
      Program trial with canagliflozin. Despite the benefits observed in these two pivotal trials,&#xD;
      the mechanisms responsible for beneficial effects of SGLT2i in patients with T2D with respect&#xD;
      to the development and/or worsening of HF are not currently known.&#xD;
&#xD;
      In light of the results of EMPA-REG OUTCOME, the investigators aim to elucidate the&#xD;
      mechanisms whereby the SGLT2i &quot;ertugliflozin&quot; modifies cardiorenal interactions that regulate&#xD;
      fluid volume and neurohormonal activation in patients with T2D and HF (T2D-HF). The&#xD;
      investigators will test the hypothesis that ertugliflozin increases proximal tubular&#xD;
      natriuresis, thereby reducing plasma volume, without inducing significant renal&#xD;
      vasoconstriction or activation of the sympathetic nervous system (SNS) (see below, Figure 1).&#xD;
      The systematic understanding of the effects of SGLT2i in the setting of HF will enable the&#xD;
      design of rational physiology based strategies to decrease the burden of HF, which could have&#xD;
      major clinical and research implications internationally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">May 7, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to 15 mg (10mg + 5mg tablets) PO ertugliflozin daily or a matched placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proximal sodium reabsorption (FENa)</measure>
    <time_frame>Outcome will be measured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>The difference in proximal sodium reabsorption FENa (measured using FELi) with ertugliflozin vs. placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Glomerular Filtration Rate (GFR, based on plasma inulin clearance) will be measured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>The difference in GFR with ertugliflozin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective Renal Plasma Flow (ERPF)</measure>
    <time_frame>Effective Renal Plasma Flow (ERPF, based on paraaminohippurate plasma clearance) will be measured at 2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>The difference in ERPF with ertugliflozin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic blood pressure (SBP)</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>The difference in SBP with ertugliflozin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic blood pressure (DBP)</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>The difference in DBP with ertugliflozin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (HR)</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>The difference in HR with ertugliflozin vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography for markers of systolic and diastolic function, cardiac output</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma volume</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Plasma volume will be measured using a non-radioactive technique (indocyanine green dilution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracellular water</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Extracellular water will be measured non-invasively using bioimpedence spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Cardiac output will also be measured using non-invasive cardiac monitoring (NICOM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic vascular resistance</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Systemic vascular resistance will also be measured using non-invasive cardiac monitoring (NICOM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAAS hormones</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Neurohormones/biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuretic peptides</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Neurohormones/biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sympathetic nervous system markers</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Neurohormones/biomarkers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary adenosine</measure>
    <time_frame>2 time points: acute (1 week) and chronic (12 weeks)</time_frame>
    <description>Neurohormones/biomarkers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Ertuglifozin Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Matching Ertugliflozin Tablet for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertugliflozin</intervention_name>
    <description>Ertugliflozin Tablets Total Dose 15mg (10mg + 5 mg) once daily for 12 weeks</description>
    <arm_group_label>Ertuglifozin Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 12 weeks</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects diagnosed with T2D ≥12 months prior to informed consent;&#xD;
&#xD;
          2. eGFR ≥30 ml/min/1.73m2;&#xD;
&#xD;
          3. Age &gt;18 years;&#xD;
&#xD;
          4. HbA1c 6.5%-10.5%;&#xD;
&#xD;
          5. Body Mass Index (BMI) 18.5-45.0 kg/m2;&#xD;
&#xD;
          6. Blood pressure ≤160/110 and ≥90/60 at screening,&#xD;
&#xD;
          7. Heart failure with New York Heart Association (NYHA) class 2-3 symptoms and ejection&#xD;
             fraction ≥20%&#xD;
&#xD;
          8. Stable dose of maximally tolerated ACE inhibitor, angiotensin receptor blocker or&#xD;
             renin inhibitor for at least 30 days&#xD;
&#xD;
          9. Stable diuretic dose for at least 30 days at the time of baseline physiological&#xD;
             assessment&#xD;
&#xD;
         10. BNP levels at baseline ≥100 pg/ml (no atrial fibrillation), ≥200 pg/ml if in atrial&#xD;
             fibrillation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type 1 Diabetes;&#xD;
&#xD;
          2. Leukocyte and/or nitrite positive urinalysis that is untreated;&#xD;
&#xD;
          3. Severe hypoglycaemia within 2 months prior to screening;&#xD;
&#xD;
          4. History of brittle diabetes or hypoglycaemia unawareness based on investigator&#xD;
             judgement;&#xD;
&#xD;
          5. Unstable coronary artery disease with acute coronary syndrome, percutaneous&#xD;
             intervention or bypass surgery within 3 months;&#xD;
&#xD;
          6. Clinically significant valvular disease;&#xD;
&#xD;
          7. Congestive heart failure secondary to an infiltrative cardiomyopathic process (for&#xD;
             example amyloid) or pericardial constriction;&#xD;
&#xD;
          8. Uncontrolled systemic hypertension (systolic blood pressure &gt;160 mmHg and/or diastolic&#xD;
             blood pressure &gt;110) or systemic hypotension (systolic blood pressure &lt; 90/60 mmHg);&#xD;
&#xD;
          9. Bariatric surgery or other surgeries that induce chronic malabsorption;&#xD;
&#xD;
         10. Anti-obesity drugs or diet regimen and unstable body weight three months prior to&#xD;
             screening;&#xD;
&#xD;
         11. Treatment with systemic corticosteroids;&#xD;
&#xD;
         12. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells;&#xD;
&#xD;
         13. Pre-menopausal women who are nursing, pregnant, or of child-bearing potential and not&#xD;
             practicing an acceptable method of birth control;&#xD;
&#xD;
         14. Participation in another trial with an investigational drug within 30 days of informed&#xD;
             consent;&#xD;
&#xD;
         15. Alcohol or drug abuse within three months prior to informed consent that would&#xD;
             interfere with trial participation or any ongoing clinical condition that would&#xD;
             jeopardize subject safety or study compliance based on investigator judgement;&#xD;
&#xD;
         16. Liver disease, defined by serum levels of alanine transaminase, aspartate&#xD;
             transaminase, or alkaline phosphatase &gt;3 x upper limit of normal as determined during&#xD;
             screening;&#xD;
&#xD;
         17. Active malignancy at the time of screening;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vesta Lai, RN</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8508</phone_ext>
    <email>vesta.lai@uhn.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuliya Lytvyn, PhD</last_name>
    <email>julia.lytvyn@mail.utoronto.ca</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Health Network, Toronto</investigator_affiliation>
    <investigator_full_name>David Z.I. Cherney</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Clinician Scientist</investigator_title>
  </responsible_party>
  <keyword>SGLT2 inhibtion</keyword>
  <keyword>Ertugliflozin</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertugliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

